114,228 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, Holdings Channel reports. The firm purchased 114,228 shares of the medical research company’s stock, valued at approximately $8,456,000.

Several other institutional investors have also recently bought and sold shares of the business. Chicago Partners Investment Group LLC lifted its position in Edwards Lifesciences by 8.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 7,055 shares of the medical research company’s stock valued at $498,000 after acquiring an additional 542 shares in the last quarter. Baxter Bros Inc. lifted its holdings in shares of Edwards Lifesciences by 1.8% in the third quarter. Baxter Bros Inc. now owns 85,268 shares of the medical research company’s stock valued at $5,627,000 after purchasing an additional 1,510 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Edwards Lifesciences by 7.7% during the third quarter. Van ECK Associates Corp now owns 126,764 shares of the medical research company’s stock valued at $8,951,000 after buying an additional 9,011 shares during the last quarter. Forum Financial Management LP bought a new stake in Edwards Lifesciences during the third quarter worth $203,000. Finally, National Pension Service grew its holdings in Edwards Lifesciences by 9.2% during the third quarter. National Pension Service now owns 1,584,579 shares of the medical research company’s stock worth $104,566,000 after buying an additional 133,182 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Friday, February 28th. The stock was sold at an average price of $70.78, for a total transaction of $796,275.00. Following the sale, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at $2,150,791.86. This represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,739 shares of company stock valued at $2,799,104. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Up 0.3 %

Edwards Lifesciences stock opened at $71.61 on Monday. The firm has a 50 day simple moving average of $72.64 and a 200 day simple moving average of $70.29. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market capitalization of $42.24 billion, a price-to-earnings ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Citigroup raised their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. The Goldman Sachs Group raised their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Piper Sandler upped their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.